Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Retatrutide (LY3437943) is a synthetic 39-amino acid triple-hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, commonly referenced in scientific literature for metabolic research, obesity mechanism studies, hepatic steatosis models, and energy expenditure pathway investigations in laboratory and preclinical environments
Maintain open communication with your doctor and work closely with them to ensure a safe health journey with the most effective and tolerable treatment plan.
7
6 A higher 7.2 mg dose of Wegovy has since been approved by the MHRA (January 2026)
Dizziness and sulfur burps are less common but still reported regularly
The odds of achieving 10%, 15%, and 20% or more weight loss were significantly higher with semaglutide (70.9%, 55.6%, and 38.5%, respectively) compared to liraglutide (25.6%, 12.0%, and 6.0%)
US$ 22.51
US$ 24.32
US$ 28.18
US$ 21.57
US$ 27.89
